<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000640</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 108</org_study_id>
    <secondary_id>11083</secondary_id>
    <nct_id>NCT00000640</nct_id>
  </id_info>
  <brief_title>A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS</brief_title>
  <official_title>A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jacobus Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of two oral treatments for mild to moderate Pneumocystis&#xD;
      carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a&#xD;
      standard treatment program of sulfamethoxazole/trimethoprim (SMX/TMP) to assess the tolerance&#xD;
      of these two alternative treatments as compared to the standard treatment of SMX/TMP. Per&#xD;
      09/09/92 amendment, to assess the efficacy and tolerance of these two alternative treatments&#xD;
      in patients who are intolerant to SMX/TMP.&#xD;
&#xD;
      The type of treatment being studied has the advantages of wide applicability throughout the&#xD;
      world (including developing countries) and low cost. An oral treatment is more accessible to&#xD;
      patients than drugs given by injection or by inhalation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The type of treatment being studied has the advantages of wide applicability throughout the&#xD;
      world (including developing countries) and low cost. An oral treatment is more accessible to&#xD;
      patients than drugs given by injection or by inhalation.&#xD;
&#xD;
      Patients with confirmed PCP are randomized into one of three treatment groups. Group A&#xD;
      receives SMX/TMP. Half of group A receives dapsone placebo (placebo is an inactive substance)&#xD;
      daily plus trimethoprim placebo; the other half receives clindamycin placebo plus primaquine&#xD;
      placebo. Group B is given dapsone plus trimethoprim. Half of group B receives SMX/TMP&#xD;
      placebo; the other half receives clindamycin placebo plus primaquine placebo. Group C is&#xD;
      given clindamycin plus primaquine. Half of group C receives SMX/TMP placebo, the other half&#xD;
      receives dapsone placebo plus trimethoprim placebo. Treatment lasts 21 days; dosages will be&#xD;
      adjusted for patients weighing less than 50 kg and more than 80 kg. Patients with a history&#xD;
      of intolerance to SMX/TMP for whom rechallenge is considered medically contraindicated may be&#xD;
      randomized to one of the non-sulfamethoxazole-containing arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1994</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>290</enrollment>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole-Trimethoprim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
          -  Maintenance treatment with investigational triazoles (e.g., itraconazole).&#xD;
&#xD;
          -  Antiemetics for nausea/vomiting, antihistamines for rash/pruritus, antipyretics for&#xD;
             systemic symptoms (fever, headache, etc.) should be used for treatment of symptoms.&#xD;
&#xD;
          -  Nonsteroidal antiinflammatory agents may be used for control of myalgias, headache,&#xD;
             etc.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Blood transfusions.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Willing and able to sign informed consent. Patients under 18 years of age may enter&#xD;
             with consent of parent or guardian.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Up to 24 hours of treatment with sulfamethoxazole/trimethoprim (SMX/TMP), dapsone /&#xD;
             trimethoprim, or clindamycin / primaquine, or one dose of pentamidine for this episode&#xD;
             of Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Prior PCP prophylaxis.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Adjunctive prednisone therapy in patients with (A-a) DO2 of 35 - 45 torr receiving&#xD;
             acute anti-PCP treatment.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions and diseases are excluded:&#xD;
&#xD;
        Positive screen for glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  Known NAD methemoglobin reductase deficiency and/or known hemoglobin M abnormality.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  GM-CSF or G-CSF. Rifampin.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Corticosteroids (in patients with baseline (A-a) DO2 &lt; 35 torr). Investigational drugs&#xD;
             not specifically allowed.&#xD;
&#xD;
          -  Folinic acid.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Previous dose-limiting intolerance to sulfones, trimethoprim, clindamycin, or&#xD;
             primaquine.&#xD;
&#xD;
        Requirement for other medications potentially effective in the treatment of Pneumocystis&#xD;
        carinii pneumonia (PCP) (e.g., pyrimethamine and sulfadiazine).&#xD;
&#xD;
          -  Prior enrollment in ACTG 108. Presence of other concurrent pulmonary pathology that&#xD;
             would make interpretation of response to antipneumocystis therapy difficult.&#xD;
&#xD;
        Inability to take oral therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acute treatment doses of anti-Pneumocystis carinii pneumonia agents within 30 days&#xD;
             prior to study entry except as noted above.&#xD;
&#xD;
          -  Systemic steroids above adrenal replacement doses within 7 days prior to study entry&#xD;
             (except for patients with (A-a) DO2 of 35 - 45 torr who receive prednisone in&#xD;
             conjunction with acute anti-PCP treatment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safrin S</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Black JR</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med. Ctr.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Mateo County AIDS Program</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Hawaii at Manoa, Leahi Hosp.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp. of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - East Campus A0102 CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University A2201</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med. Ctr., Dept. of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas HealthCare System, Carolinas Med. Ctr.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Center for Infectious Disease, Wendover Medical Center CRS</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wu AW, Gray S, Brookmeyer R, Safrin S. Quality of life in a double-blind randomized trial of 3 oral regimens for mild-to-moderate Pneumocystis carinii pneumonia in AIDS (ACTG 108). Int Conf AIDS. 1996 Jul 7-12;11(1):229 (abstract no TuB112)</citation>
  </reference>
  <reference>
    <citation>Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, Cheung T, Soeiro R, Hojczyk P, Black JR. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996 May 1;124(9):792-802. doi: 10.7326/0003-4819-124-9-199605010-00003.</citation>
    <PMID>8610948</PMID>
  </reference>
  <reference>
    <citation>Rubin HR, Wu AW, Gutierrez M, Liriano O, Safrin S. Spanish translation of a functional status questionnaire for Pneumocystis carinii pneumonia. Int Conf AIDS. 1992 Jul 19-24;8(2):B178 (abstract no PoB 3549)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Dapsone</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Clindamycin</keyword>
  <keyword>Sulfamethoxazole-Trimethoprim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

